{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-058332","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2026-05-11T13:01:36+00:00","discovered_at":"2026-05-11T14:49:57.127956+00:00","generated_at":"2026-05-11T18:21:10.954037+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"MetaVia DA-1726 late-breaking abstract accepted for EASL 2026 poster; Phase 1 data expected Q4","bullets":["Abstract LB26-5204 on DA-1726 (GLP-1/glucagon dual agonist) accepted for poster at EASL Congress 2026 in Barcelona (May 27-30).","Poster title: Safety, Tolerability, PK, PD of DA-1726 in higher-dose Phase 1 cohort with exploratory liver assessment.","Phase 1 Part 3 titration study ongoing; optimizing higher dose levels and tolerability; data expected Q4 2026.","Presenting author: Chris Fang, CMO; poster available on MetaVia website after presentation."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-058332","json":"https://secwatch.observer/filing/0001104659-26-058332.json","markdown":"https://secwatch.observer/filing/0001104659-26-058332.md","text":"https://secwatch.observer/filing/0001104659-26-058332.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926058332/0001104659-26-058332-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926058332/mtva-20260511x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T18:21:10.954037+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}